Capsaicin is under clinical development by Grunenthal and currently in Phase III for Chemotherapy Induced Peripheral Neuropathy. According to GlobalData, Phase III drugs for Chemotherapy Induced Peripheral Neuropathy does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Capsaicin LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Capsaicin overview
Capsaicin (Qutenza) is an alkylamide found in capsicum. It is formulated as patch and gel for topical, transdermal or cutaneous application. Qutenza is indicated in adults for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and for neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet.
The drug candidate is under development for the treatment for post-surgical neuropathic pain, chemotherapy induced peripheral neuropathy and it was under development for the management of neuropathic pain (nerve pain) related to HIV associated peripheral neuropathy (HIV-PN).
Grunenthal overview
Grunenthal is a research-oriented pharmaceutical company that researches, develops and markets products for the treatment of pain management and related diseases. Its portfolio includes a wide range of medicinal products for chronic and acute pain, nociceptive and neuropathic pain. The company’s products portfolio include Tramal used for the treatment of moderate to severe pain; Transtec used to treat moderate to severe cancer pain; and Vimovo used for the treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. The company distributes products and operates in Europe, Latin America and the US. Grunenthal is headquartered in Aachen, Nordrhein-Westfalen, Germany.
For a complete picture of Capsaicin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
